Back to search
FDAFDA · Food and drugs·Recall number D-1496-2016

Eptifibatide Injection 75 mg/100 mL (0.75 mg/mL) single use vial, For Intravenous Use Only, Rx Only, Manufactured in Hungary for TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC# 0703-1179-01.

Published September 14, 2016 · Recall initiated: June 17, 2016

Summary

FDA records drug Class II recall D-1496-2016, published September 14, 2016 and initiated June 17, 2016. Recalling firm: Teva North America; Status: Terminated; Reported quantity: 14,661 vials; Lot: All Lots Within Expiry Lot# 2710715, 2720715, 2730715, 3110715, 3120715. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva North America
Distributor
Nationwide and Puerto Rico
Lot
All Lots Within Expiry Lot# 2710715, 2720715, 2730715, 3110715, 3120715
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Eptifibatide Injection 75 mg/100 mL (0.75 mg/mL) single use vial, For Intravenous Use Only, Rx Only, Manufactured in Hungary for TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC# 0703-1179-01. recalled?

Yes. FDA published recall D-1496-2016 on September 14, 2016. Reported hazard: CGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter